EUVIMEDEUVIMED entdecken
Crossref

Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study

Aymen Hişmioğullari, Özlem Sancakli, Soner Günder, Özgen Soyöz, Ayça Demir, Figen Çelebi Çelik, Berna Uzunoğlu, Gülçin Kaymakoğlu, Necmi Can Yüksel, Emre Firat, Canan Şule Karkiner, Demet Can

International Archives of Allergy and Immunology · 23.06.2026 · 1-10

DOI: 10.1159/000553219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, online erschienen am 23.06.2026. Verfasst von Aymen Hişmioğullari und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Allergy Department, Dr. Behçet Uz Children's Hospital, Izmir, Turkey, eymen_hismi@hotmail.com. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Omalizumab is an effective therapy for H1-antihistamine-refractory chronic spontaneous urticaria (CSU). However, predictive biomarkers for treatment success in the pediatric population remain poorly defined. This study aimed to identify clinical and laboratory factors predicting complete disease control in children receiving omalizumab.

Methods

We conducted a retrospective cohort study of 44 pediatric patients (aged 12–18 years) with CSU treated with omalizumab (300 mg/4 weeks). Disease activity and control were assessed using Urticaria Activity Score (UAS7), Urticaria Control Test (UCT), and Chronic Urticaria Quality of Life Questionnaire at baseline and months 1, 3, and 6. Complete control was defined as UAS7 = 0 and UCT = 16 at month 6. Univariate and multivariate logistic regression analyses were performed to identify independent predictors.

Results

Complete control was achieved in 40.9% (n = 18) of patients at month 6. In multivariate analysis, shorter symptom duration prior to omalizumab (odds ratio [OR]: 0.46; 95% confidence interval [CI]: 0.25–0.88) and higher baseline absolute eosinophil count (OR: 1.04; 95% CI: 1.00–1.06) were identified as independent predictors of complete control. In addition, early clinical response at month 1 was significantly associated with subsequent treatment success and may serve as an early on-treatment prognostic marker.

Conclusion

Early initiation of omalizumab and higher baseline eosinophil counts are strong predictors of complete disease control in pediatric CSU. These findings support a biomarker-guided and timely intervention strategy to optimize clinical outcomes in children.

Schlagwörter

Stichwörter der Autor:innen

Chronic spontaneous urticariaEosinophilsOmalizumabPediatricsTreatment

Autor:innen und Institutionen

  • Pediatric Allergy Department, Dr. Behçet Uz Children's Hospital, Izmir, Turkey, eymen_hismi@hotmail.com.
  • Pediatric Allergy Department, Dr. Behçet Uz Children's Hospital, Izmir, Turkey.
  • Department of Pediatric Immunology and Allergy, Çiğli Training and Research Hospital, Bakırçay University, Izmir, Turkey.
  • Department of Pediatric Immunology and Allergy, Muğla Training and Research Hospital, Muğla, Turkey.
  • University of Health Sciences, İzmir Tepecik Training and Research Hospital, Izmir, Turkey.

Zitieren

APA

Hişmioğullari, A., Sancakli, Ö., Günder, S., Soyöz, Ö., Demir, A., Çelebi Çelik, F., Uzunoğlu, B., Kaymakoğlu, G., Yüksel, N. C., Firat, E., Karkiner, C. Ş., & Can, D. (2026). Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study. International Archives of Allergy and Immunology, 1-10. https://doi.org/10.1159/000553219

Vancouver

Hişmioğullari A, Sancakli Ö, Günder S, Soyöz Ö, Demir A, Çelebi Çelik F, et al. Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study. International Archives of Allergy and Immunology. 2026:1-10. doi:10.1159/000553219

BibTeX
@article{Himioullari2026,
  author = {Hişmioğullari, Aymen and Sancakli, Özlem and Günder, Soner and Soyöz, Özgen and Demir, Ayça and Çelebi Çelik, Figen and Uzunoğlu, Berna and Kaymakoğlu, Gülçin and Yüksel, Necmi Can and Firat, Emre and Karkiner, Canan Şule and Can, Demet},
  title = {Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study},
  journal = {International Archives of Allergy and Immunology},
  year = {2026},
  pages = {1--10},
  doi = {10.1159/000553219}
}
Kostenlos starten →